Funding sources This work is supported in part by grant PI10/00785 from Fondo de Investigación Sanitaria, Instituto de Salud Carlos III, Ministerio de Ciencia e Innovación and grant RD09/0076/00036 from Instituto de Salud Carlos III FEDER; and the ‘Xarxa de Bancs de tumours’ sponsored by ‘Pla Director d'Oncologia de Catalunya (XBTC)’.
Evaluation of MYC status in oral lichen planus in patients with progression to oral squamous cell carcinoma
Version of Record online: 8 JUL 2013
© 2013 The Authors BJD © 2013 British Association of Dermatologists
British Journal of Dermatology
Volume 169, Issue 1, pages 106–114, July 2013
How to Cite
Segura, S., Rozas-Muñoz, E., Toll, A., Martín-Ezquerra, G., Masferrer, E., Espinet, B., Rodriguez, M., Baró, T., Barranco, C. and Pujol, R.M. (2013), Evaluation of MYC status in oral lichen planus in patients with progression to oral squamous cell carcinoma. British Journal of Dermatology, 169: 106–114. doi: 10.1111/bjd.12303
Conflicts of interest None declared.
- Issue online: 8 JUL 2013
- Version of Record online: 8 JUL 2013
- Accepted manuscript online: 6 MAR 2013 01:41AM EST
- Manuscript Accepted: 26 FEB 2013
Malignant transformation of oral lichen planus (OLP) to oral squamous cell carcinoma (OSCC) is controversial. C-MYC is a proto-oncogene involved in various solid tumours, including OSCC.
To determine MYC status using fluorescence in situ hybridization (FISH) and immunohistochemistry (IHC) in OLP lesions from 10 patients with progression to OSCC (group I) and to compare this with OLP lesions from patients without progression to OSCC (group II).
We constructed two tissue microarrays with 11 OSCC samples (group IA), 17 OLP samples from the same patients (group IB) and 13 OLP specimens from 12 control patients (group II). FISH evaluation of the MYC gains was determined in 100 nonoverlapping nuclei per sample. IHC evaluation was determined by calculating the percentage C-MYC expression in the epithelial cells.
OSCC samples showed MYC copy number gains and C-MYC overexpression in 91% and 73% of cases, respectively. MYC gains were detected in 47% of samples from group IB and were absent from all samples from group II. C-MYC was overexpressed in 87% of cases from group IB and in only 44% of control specimens (group II). The differences in MYC status between groups IB and II were statistically significant.
OLP lesions in patients with progression to OSCC show MYC gains and C-MYC overexpression. In patients with severe OLP, determining MYC status may predict a subgroup of subjects with a higher risk of progression to OSCC.